- Home
- VERV vs NMM Comparison
VERV vs NMM Comparison
Compare VERV & NMM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- VERV
- NMM
- Stock Information
- Founded
- VERV 2018
- NMM 2007
- Country
- VERV United States
- NMM Greece
- Employees
- VERV N/A
- NMM N/A
- Industry
- VERV Medicinal Chemicals and Botanical Products
- NMM Marine Transportation
- Sector
- VERV Health Care
- NMM Consumer Discretionary
- Exchange
- VERV Nasdaq
- NMM Nasdaq
- Market Cap
- VERV 1.0B
- NMM 1.1B
- IPO Year
- VERV 2021
- NMM 2007
- Fundamental
- Price
- VERV $11.06
- NMM $39.83
- Analyst Decision
- VERV Buy
- NMM Strong Buy
- Analyst Count
- VERV 11
- NMM 1
- Target Price
- VERV $14.57
- NMM $80.00
- AVG Volume (30 Days)
- VERV 7.6M
- NMM 93.3K
- Earning Date
- VERV 08-07-2025
- NMM 08-19-2025
- Dividend Yield
- VERV N/A
- NMM 0.52%
- EPS Growth
- VERV N/A
- NMM N/A
- EPS
- VERV N/A
- NMM 11.16
- Revenue
- VERV $59,613,000.00
- NMM $1,319,623,000.00
- Revenue This Year
- VERV $47.32
- NMM N/A
- Revenue Next Year
- VERV N/A
- NMM $7.93
- P/E Ratio
- VERV N/A
- NMM $3.59
- Revenue Growth
- VERV 271.44
- NMM 0.28
- 52 Week Low
- VERV $2.87
- NMM $28.37
- 52 Week High
- VERV $11.41
- NMM $65.89
- Technical
- Relative Strength Index (RSI)
- VERV 78.23
- NMM 57.44
- Support Level
- VERV $11.16
- NMM $37.42
- Resistance Level
- VERV $11.30
- NMM $39.52
- Average True Range (ATR)
- VERV 0.12
- NMM 1.18
- MACD
- VERV -0.18
- NMM 0.02
- Stochastic Oscillator
- VERV 12.50
- NMM 85.15
About VERV Verve Therapeutics Inc.
Verve Therapeutics Inc clinical-stage company developing a new class of genetic medicines for cardiovascular disease, or CVD, with the potential to transform treatment from chronic therapies to single-course gene editing medicines. The current paradigm of chronic care is fragile requiring rigorous patient adherence, extensive healthcare infrastructure, and regular healthcare access, and leaves many patients without adequate care. Its pipelines are PCSK9, ANGPTL3, and LPA. The group has one reportable segment relating to the research and development of gene-editing medicines. The segment derives its current revenues from research and development collaborations.
About NMM Navios Maritime Partners LP Common Units Representing Limited Partner Interests
Navios Maritime Partners LP is a seaborne shipping company. It owns and operates dry cargo and container vessels with the primary long-term and staggered expiration charters. The firm's fleet consists of Ultra- Handymax, Panamax, Capsize, and Container vessels and categorized in Drybulk and Container vessels. It earns revenue through the chartering of vessels and voyage contracts. Geographically, it generates majority revenue from Asia.